Pharma Study 6: Syndicated Stock Availability Research

In 2011 we created a study that allowed pharmacos to benchmark their performance of products that are frequently exported from the UK. It is vital that these stocks are managed well to prevent excessive delays occuring for pharmacists and patients.

The results of the survey has allowed a number of pharmacos to assess their relative performance in stock delays versus their competitors. In some cases, the results have been used to evidence a good or reasonable performance to internal and external stakeholders. This has supported key decisions such as whether to amend stock allocations and/or distribution processes.